Table 1.
Patient characteristics
| Characteristics | Overall No. (%) | Males No. (%) | Females No. (%) | p value |
|---|---|---|---|---|
| Total patients | 1827 (100) | 1352 (100) | 475 (100) | – |
| Age (years) | ||||
| 18–49 | 240 (13) | 180 (13) | 60 (13) | 0.999 |
| 50–69 | 1046 (57) | 780 (58) | 266 (56) | |
| ≥ 70 | 541 (30) | 392 (29) | 149 (31) | |
| Clear cell histology | 1578 (86) | 1170 (87) | 408 (86) | 0.837 |
| Non-clear cell histology | 249 (14) | 182 (13) | 67 (14) | 0.837 |
| Papillary | 97 (5) | 73 (5) | 24 (5) | 1.000 |
| Chromophobe | 36 (2) | 25 (2) | 11 (2) | 1.000 |
| Other | 116 (6) | 84 (6) | 32 (7) | 0.775 |
| Sarcomatoid differentiation | 274 (15) | 180 (13) | 94 (20) | 0.184 |
| Metastatic at diagnosis | 1034 (57) | 758 (56) | 276 (58) | 0.776 |
| Previous nephrectomy | 1179 (65) | 881 (65) | 298 (63) | 0.769 |
| No. of metastatic sites > 2 | 532 (29) | 396 (29) | 136 (29) | 1.000 |
| Site of metastasis, individual | ||||
| Lung | 1251 (68) | 947 (70) | 304 (64) | 0.368 |
| Lymph node | 614 (34) | 445 (33) | 169 (36) | 0.656 |
| Liver | 323 (18) | 225 (17) | 98 (21) | 0.472 |
| Bone | 603 (33) | 451 (34) | 152 (32) | 0.764 |
| Brain | 129 (7) | 88 (7) | 41 (9) | 0.603 |
| IMDC Prognostic Risk Group | ||||
| Favorable | 259 (14) | 194 (14) | 65 (14) | 1.000 |
| Intermediate | 1139 (62) | 852 (63) | 287 (60) | 0.664 |
| Poor | 429 (24) | 306 (23) | 123 (26) | 0.623 |
| NLR ≥ 4 | 533 (29) | 390 (29) | 143 (30) | 0.877 |
| BMI ≥ 25 | 1154 (63) | 899 (66) | 255 (54) | 0.084 |
BMI, Body Mass Index; IQR, interquartile range; NLR, Neutrophil-to-Lymphocyte Ratio